This approval, granted by the U.S. FDA on 8 May 2020, was based on the efficacy and safety findings of selpercatinib among patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), and metastatic RET-mutant medullary thyroid cancer and metastatic RET fusion-positive thyroid cancer from a single-arm, phase 1–2, LIBRETTO-001 trial (NCT03157128) [12,14,15,16,17]. Here, RET is linked to thyroid gland carcinoma.